

SARS-CoV-2 Pseudoviral Particles, Alpha Variant (UK B.1.1.7)

Cat. No. SARS-CoV-2-15PsV **Lot. No.** (See product label)

SPECIFICATION

Product Overview

Our SARS-CoV-2-UK Pseudoviral Particles are replication-deficient MLV pseudotyped with the SARS-CoV-2 spike protein of the Alpha variant, originally known as UK variant B.1.1.7, VOC 202012/01, 201/501Y.V1). They also contain the ORF for firefly luciferase as a reporter. They establish a pseudovirus cell entry assay mediated by the SARS-CoV-2 spike protein that can be conveniently measured via luciferase reporter activity. This pseudovirus assay isolates the SARS-CoV-2 viral entry from other steps of the viral infection cycle.

Species SARS-CoV-2

Description

It has been known that SARS-CoV-2 and SARS-CoV both use human ACE2 as entry receptor and human proteases as entry activators. The virus surface spike protein (S) mediates SARS-CoV-2 entry into cells. To fulfill its function, SARS CoV-2 spike binds to its human ACE2 (hACE2) receptor through its receptor-binding domain (RBD) and is proteolytically activated by human proteases.

Usage

Note: requires a luciferase assay reagent.

Cell Infection:

1. Count HEK293-ACE2 cells to be infected and seed ~20K cells per well into 96-well plates (50 µL per well) DMEM with 10% Serum (no antibiotics) or 5K cells per well into 384-well plates (15 µL per well).
2. Culture cells overnight to make sure the cells stably adhere to the plates.
3. On the 2nd day, remove media, add 50 µL SARS-CoV-2-UK Pseudoviral Particles* into each well (12.5 µL for 384-well plate). Spin at 700 rpm for 15 min at 4 centigrade.

 Tel: 1-631-559-9269 1-516-512-3133

 Email: info@creative-biomart.com  Fax: 1-631-938-8127

 45-1 Ramsey Road, Shirley, NY 11967, USA

*Note: thaw the pseudoviral particles quickly in the room temperature water (< 30 minutes, do not shake) and use right away. Discard the unused portion (do not re-freeze or leave it on ice for later use).

4. Incubate for 2 hrs at 37 centigrade.

5. Add 50 µL DMEM with 10% FC into each well (12.5 µL for 384-well plates).

6. Incubate for 42 hrs at 37 centigrade.

Measurement of Luciferase Activity in Infected Cells

1. Do not remove medium. Add 100 µL luciferase assay WORKING SOLUTION (25 µL for 384-well plate) directly into each well.

2. Read in a luminescence plate reader and record the data.

Applications

Our Pseudovirus Particles generate robust chemiluminescent signals in cell assays when coupled with our firefly luciferase assay kit, useful for:

- 1) screening potential inhibitor to block SARS-CoV-2 entry and viral protein translation;
- 2) measuring the activity of and screening for neutralizing antibody against SARS-CoV-2-UK.

Shelf Life

Six months from the date of shipping when stored at -70 centigrade.

Features

Robust: Excellent signal to noise (basal) ratio

Easy to use: Amenable to HTS format (96-well, 384-well and 1536-well format)

Storage

At -70 centigrade.

Shipping

Shipped on dry ice.

References

1. Development and Characterization of Phage-Display-Derived Novel Human Monoclonal Antibodies against the Receptor Binding Domain of SARS-CoV-2.

 Tel: 1-631-559-9269 1-516-512-3133

 Email: info@creative-biomart.com  Fax: 1-631-938-8127

 45-1 Ramsey Road, Shirley, NY 11967, USA

Biomedicines 2022, 10(12), 3274

**Pseudoviral Particle
(PP) Infection
Assays**

SARS-CoV-2-UK variant pseudoviral particles on HEK293-ACE2 cells in 384-well format.

**Illustration of the
replication-deficient
MLV particle
pseudotyped with
SARS-CoV-2 Spike
protein** Tel: 1-631-559-9269 1-516-512-3133 Email: info@creative-biomart.com  Fax: 1-631-938-8127 45-1 Ramsey Road, Shirley, NY 11967, USA